Please ensure Javascript is enabled for purposes of website accessibility
Home / Opinion Digests / Products liability – Lupron – Settlement

Products liability – Lupron – Settlement

A U.S. District Court judge presiding over a Lupron class action that was settled for $150 million committed no abuse of discretion in distribution $11.4 million in unclaimed funds to the Dana Farber/Harvard Cancer Center and the Prostate Cancer Foundation for work on the treatment of the diseases for which Lupron is prescribed.

In Re: Lupron Marketing and Sales Practices Litigation (Lawyers Weekly No. 01-108-12) (39 pages) (Lynch, C.J.) (1st Circuit) Appealed from a decision by Stearns, J., in the U.S. District Court for the District of Massachusetts. Donald E. Haviland Jr., with whom Michael J. Lorusso and Haviland Hughes were on brief, for appellants; Thomas M. Sobol, with whom Edward Notargiacomo, Hagens Berman Sobol Shaprio, Jeffrey L. Kodroff, John A. Macoretta, Specter Roseman & Kodroff, David S. Stellings, Daniel R. Leathers, Lieff Cabraser Heimann & Bernstein, Lisa M. Mezzetti, and Cohen Milstein Sellers & Toll were on brief, for appellee William M. Porter; Martin M. Fantozzi, with whom Mariana Korsunsky and Goulston & Storrs were on brief, for appellee Dana Farber/Harvard Cancer Center (Docket Nos. 10-2494 and 11-1329) (April 24, 2012).

Leave a Reply

Your email address will not be published. Required fields are marked *